MedTrace Logo

Lactoferrin Prophylaxis in VLBW and Regulator T-cells

NCT01287507 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2014-08-26

No results posted yet for this study

Summary

The aim of the study is to evaluate whether oral administration of 200 mg/day lactoferrin (LF) to very low birth weight infants reduces late onset sepsis and necrotising enterocolitis and the effect of LF on regulatory T cells.

Conditions

  • Late Onset Neonatal Sepsis
  • Necrotising Enterocolitis
  • Very Low Birth Weight Infants

Interventions

DIETARY_SUPPLEMENT

Lactoferrin (bovine origin)

Bovine lactoferrin 200 mg/daily, given with either human milk or preterm formula

Sponsors & Collaborators

  • Ankara University

    lead OTHER

Principal Investigators

  • Saadet Arsan, Prof · Anlara University Chief of Neonatology

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
15 Minutes
Max Age
1 Day
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2011-01-31
Completion
2011-12-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01287507 on ClinicalTrials.gov